Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1651858

This article is part of the Research TopicImmune-genetic dynamics in disease progression and therapeutic strategiesView all 6 articles

The Osteosarcoma Immune Microenvironment in Progression: PLEK as a Prognostic Biomarker and Therapeutic Target

Provisionally accepted
Yunpeng  ZouYunpeng Zou1Jianning  KangJianning Kang2,3Shaopeng  ZhuShaopeng Zhu1Xuechen  RenXuechen Ren4Zheng  LiZheng Li5Jiayao  NiuJiayao Niu5Xuanzhe  QinXuanzhe Qin1Hongbo  LiHongbo Li1Lu  XiangLu Xiang5Wei  JiangWei Jiang5Jiangbo  ZhongJiangbo Zhong5*Ying  ZhangYing Zhang5,6*Kai  ZhaoKai Zhao5*
  • 1Shandong Second Medical University, Weifang, China
  • 2Shandong University, Jinan, China
  • 3Jinan Central Hospital, Jinan, China
  • 4Lanzhou University, Lanzhou, China
  • 5Central Hospital Affiliated to Shandong First Medical University, Jinan, China
  • 6Shandong University of Traditional Chinese Medicine Second Affiliated Hospital, Jinan, China

The final, formatted version of the article will be published soon.

Introduction: Osteosarcoma (OS) is a malignant bone tumor with high metastatic potential and poor long-term survival. The tumor immune microenvironment and metabolic reprogramming are increasingly recognized as key drivers of OS progression, yet the molecular links between these systems remain unclear. This study aimed to identify immune-metabolic biomarkers in OS, focusing on pleckstrin (PLEK) as a potential regulatory hub.Methods: We conducted differential expression and survival analyses using OS transcriptomic datasets and TCGA/GTEx data. Protein-protein interaction networks, GO/KEGG enrichment, and CytoHubba algorithms identified core hub genes.Tumor-infiltrating immune cells were profiled via TIMER. Single-cell RNA-seq (GSE162454) was used for immune and metabolic landscape mapping. PLEK was further validated by qRT-PCR and Western blot in OS samples, and its function assessed via siRNA knockdown in macrophages within TME co-cultured with OS cells. Cell proliferation, migration, and invasion assays evaluated phenotypic effects in OS cells. Results: Nine hub genes were identified, with PLEK significantly upregulated in OS tissues. High PLEK expression correlated with improved survival and increased infiltration of macrophages, dendritic cells, and CD4⁺ T cells. Single-cell analysis showed PLEK enrichment in macrophage-dominated clusters with active glycolytic and oxidative phosphorylation pathways. Downregulation of PLEK in macrophages enhanced OS cell proliferation, migration and invasion. These findings suggest PLEK is linked to a pro-immune, metabolically active microenvironment and may act as a tumor suppressor. Discussion: Our study identifies PLEK as a prognostic biomarker and functional regulator in OS. It promotes an immune-infiltrated, metabolically active tumor microenvironment and is associated with attenuated malignant phenotypes in vitro. These findings highlight PLEK as a promising target for immunometabolic modulation in OS.

Keywords: Osteosarcoma, immune microenvironment, Molecular Biomarkers, Multi-omics analysis, single-cell RNA sequencing, Plek

Received: 22 Jun 2025; Accepted: 28 Jul 2025.

Copyright: © 2025 Zou, Kang, Zhu, Ren, Li, Niu, Qin, Li, Xiang, Jiang, Zhong, Zhang and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Jiangbo Zhong, Central Hospital Affiliated to Shandong First Medical University, Jinan, China
Ying Zhang, Central Hospital Affiliated to Shandong First Medical University, Jinan, China
Kai Zhao, Central Hospital Affiliated to Shandong First Medical University, Jinan, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.